COMPLYADVANTAGE
26.10.2021 07:02:08 CEST | Business Wire | Press release
ComplyAdvantage , a global data technology company transforming financial crime detection, and Elliptic , the global leader in cryptoasset risk management solutions, today announced a new blockchain analysis and transaction monitoring tool that will help crypto firms detect and avoid financial crime.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005582/en/
The industry-first solution is powered by Elliptic Navigator, a crypto anti-money laundering (AML) monitoring platform. It allows fast-growing crypto firms to undertake continual AML monitoring, fraud and sanctions strategies that will help the industry avoid customers and clients who present a risk of involvement in financial crime, including the financing of terrorism.
The partnership comes at a critical time for the industry, as the ability to monitor crypto transactions has become considerably more challenging with the introduction of new services such as NFTs (non fungible tokens), privacy wallets, and decentralized finance (DeFi) networks. In response, more regulations have been published by the FATF (Financial Action Task Force) and the European Commission to provide greater certainty for any crypto assets that are not covered by existing financial services legislation.
By combining the two worlds of fiat and crypto risk assessment by integrating Elliptic’s blockchain analytics into the ComplyAdvantage platform, users will be able to consolidate their risk management processes, deep dive into blockchain transaction history and risk scoring, and reduce the time and cost spent on integrating compliance workflows between fiat and crypto.
New capabilities within the ComplyAdvantage platform include:
● Detect High-Risk Crypto Transactions — Speed up compliance checks, minimize manual intervention, and reduce costs with automated transaction risk scoring based on Elliptic’s blockchain analytics.
● Identify High-Risk Customers — Monitor your customers’ crypto activity across all of their crypto transactions. Detect suspicious activity early, using sophisticated analytics and risk indicators from Elliptic’s dataset.
● Trace Source and Destination Funds — Review where a transaction came from, or where it is being sent, by leveraging Elliptic Navigator’s blockchain tracing capabilities to determine the ultimate source or destination of funds.
● Simplify SARS Submissions — Maintain a full audit trail of crypto transactions and export complete, accurate records to submit Suspicious Activity Reports (SARs) with ease.
“Empowering businesses with bank-grade payments risk solutions that integrate fiat and crypto capabilities is a critical step towards shaping a future of finance that includes virtual assets in a secure and trusted way,” said Simone Maini, CEO, Elliptic. “Our partnership with ComplyAdvantage is an exciting opportunity to develop robust solutions that provide businesses with deep insight into a broad range of cryptoassets.”
Elliptic Navigator is powered by Elliptic’s comprehensive data engine that has collected, labelled, analyzed, and risk scored blockchain data since as early as 2013. With 98% of daily crypto transactions monitored, the world’s largest crypto businesses and financial institutions such as Coinbase, Revolut, and Santander rely on Elliptic to understand and act on risk exposure to crypto by applying the highest levels of regulatory compliance rigour.
ComplyAdvantage’s unique hyperscale approach to risk management helps to detect transaction monitoring events while uncovering hidden risks throughout the customer lifecycle, helping fintechs like Paxos maintain the highest level of compliance oversight and integrity. This reduces dependence on manual review processes and legacy databases by up to 80% and improves how businesses like Paxos screen and monitor clients and transactions.
"By working with Elliptic we now offer a more comprehensive blockchain analysis transaction monitoring solution for our rapidly growing base of crypto customers,” said Charlie Delingpole, founder and CEO of ComplyAdvantage. “Data is key to preventing financial crime and our hyperscale approach to risk management is enhanced through valuable partners like Elliptic.”
Already the preferred choice of some of the world’s largest banks, enterprises, and high-growth fintechs, ComplyAdvantage uses machine learning to help regulated organizations manage their risk obligations and prevent financial crime. ComplyAdvantage was recently named as one of the world's most innovative companies by Fintech Global .
About ComplyAdvantage
ComplyAdvantage is the financial industry’s leading source of AI-driven financial crime risk data and detection technology. ComplyAdvantage’s mission is to neutralize the risk of money laundering, terrorist financing, corruption, and other financial crime. More than 700 enterprises in 69 countries rely on ComplyAdvantage to understand the risk of who they’re doing business with through the world's only global, real-time database of people and companies. The company actively identifies tens of thousands of risk events from millions of structured and unstructured data points every single day.
ComplyAdvantage has four global hubs located in New York, London, Singapore and Cluj-Napoca and is backed by Goldman Sachs, Ontario Teachers’, Index Ventures and Balderton Capital. Learn more at complyadvantage.com or follow us on Twitter or LinkedIn .
About Elliptic
Elliptic is the global leader in cryptoasset risk management for crypto businesses and financial institutions worldwide. Recognized as a WEF Technology Pioneer and backed by investors including Wells Fargo Strategic Capital, SBI Group, and Santander Innoventures, Elliptic has assessed risk on transactions worth several trillion dollars, uncovering activities related to money laundering, terrorist fundraising, fraud, and other financial crimes. Elliptic is headquartered in London with offices in New York, Singapore, and Tokyo. To learn more, visit www.elliptic.co and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005582/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom